[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.肝脏,2015,20:750-767.
[2] Li L, Jiang W,Wang J. Clinical analysis of 275 cases of acute drug induced liver disease. Front Med China, 2007, 1:58-61.
[3] Wang Z, Liang X, Yu J, et al. Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients. J Gastroenterol Hepatol, 2012, 27:1348-1352.
[4] Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev, 2003, 55: 1293-1302.
[5] 王宏胜,翟晓文,陆凤娟,等. 培门冬酶一线治疗儿童淋巴系统肿瘤的临床研究. 中国癌症杂志,2014, 24:374-380.
[6] 丛佳,杨磊,叶进魏,等. 培门冬酶治疗淋巴系统肿瘤的不良反应及处理:来自单中心443 例次的经验. 中华血液学杂志,2018, 39:654-660.
[7] Burke PW, Aldoss I, Lunning MA, et al. Pegaspargase-related high- grade hepatotoxicity in a pediatric inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res, 2018, 66:49-56.
[8] 沈绿瑛, 林聪猛,林达义. 培门冬酶治疗成人急性淋巴细胞白血病的疗效及安全性.中国医药科学,2017, 7:75-78.
[9] 夏林玉,徐卫云. 乳腺癌化疗相关性肝损伤的研究进展. 西部医学,2017,29:737-740.
[10] 曾玲玲,周桂琴.药物性肝损害诊断标准及其临床应用.药物不良反应杂志,2011, 13:17-20. |
